Orion Corporation: Managers’ transactions – Kari Jussi Aho

Group 1 - Orion Corporation has received a notification regarding transactions made by its board member Kari Jussi Aho, specifically concerning share-based incentives [1] - The transaction occurred on April 30, 2025, involving 415 shares at a unit price of 0 EUR, indicating a receipt of a share-based incentive [1] - Orion Corporation is a Nordic pharmaceutical company with a history of over a hundred years, focusing on human and veterinary pharmaceuticals, and has a diverse portfolio including proprietary and generic medicines [2] Group 2 - In 2024, Orion's net sales reached EUR 1,542 million, and the company employed approximately 3,700 professionals globally [2] - The core therapy areas of Orion's pharmaceutical R&D include oncology and pain management, with proprietary products aimed at treating cancer, neurological diseases, and respiratory diseases [2] - Orion's shares are listed on Nasdaq Helsinki, indicating its presence in the public market [2]